What are Opus Genetics's total assets?

Opus Genetics (IRD) holds $66.8M in total assets, up 38.7% year over year.

How much debt does Opus Genetics have?

Opus Genetics carries $1.2M in total debt against -$45.8M of shareholders' equity, a debt-to-equity ratio of 0.07.

How much cash does Opus Genetics have?

Opus Genetics holds $60.0M in cash and equivalents.

Can Opus Genetics cover its short-term obligations?

Its current ratio is 7.13 — current assets exceed current liabilities.

Where does Opus Genetics's balance sheet data come from?

Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Opus Genetics IRD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$59.96M+43.5%	$45.09M+48.7%	$30.82M-15.9%	$32.43M-21.7%	$41.79M-11.4%
Accounts receivable, net	$1.73M-43.8%	$2M-44.0%	$2.92M+57.0%	$3.4M+150%	$3.08M+60.1%
Prepaid expenses and other current assets	$3.93M+185%	$1.79M+247%	$815K+90.0%	$1.43M+28.6%	$1.38M-11.5%
Total current assets	$66.6M+39.0%	$50.04M+36.7%	$35.91M-11.1%	$38.44M-14.3%	$47.93M-7.6%
Property and equipment, net	$186K-22.2%	$199K-21.0%	$212K—	$226K—	$239K—
Total assets	$66.79M+38.7%	$50.24M+36.3%	$36.12M-10.6%	$38.67M-13.8%	$48.17M-7.1%
Accounts payable	$4.42M+82.0%	$3.29M+4.6%	$2.4M+184%	$1.47M+131%	$2.43M+17.7%
Accrued expenses	$795K+54.4%	$1.99M-75.5%	$1.42M+247%	$1.33M+211%	$515K+20.6%
Total current liabilities	$9.34M-61.5%	$7.78M-31.1%	$29.09M+378%	$20.19M+381%	$24.25M+319%
Long-term debt	$1.2M—	——	——	——	——
Total liabilities	$77.35M+219%	$25.99M+130%	$30.16M+395%	$21.19M+405%	$24.25M+319%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	125M0.0%	125M+4,166,567%	125M0.0%	125M+66.7%	125M+66.7%
Additional paid-in capital	$208.28M+36.8%	$203.93M+39.9%	$178.03M+28.9%	$172.08M+25.6%	$152.26M+13.1%
Retained earnings	-$254.12M-72.6%	-$188.59M-35.7%	-$172.07M-65.7%	-$154.61M-60.5%	-$147.19M-66.2%
Total stockholders' equity	-$45.84M-1,004%	$15.35M+128%	$5.97M-82.6%	$17.47M-57.0%	$5.07M-89.0%
Total liabilities and stockholders' equity	$66.79M+38.7%	$50.24M+36.3%	$36.12M-10.6%	$38.67M-13.8%	$48.17M-7.1%
Contract assets and unbilled receivables (Note 10)	$984K—	$1.17M—	$1.36M—	$1.18M—	——
Accrued Manufacturing Costs	$795K+54.4%	$1.99M+34.5%	$1.42M+247%	$1.33M+211%	$515K+20.6%
Convertible Debt - Current	$24.74M—	$0—	$0—	——	——
Compensation and benefits	$795K+54.4%	$1.99M+34.5%	$1.42M+247%	$1.33M+211%	$515K+20.6%
Professional Service Fees Payable	$1.25M-69.3%	$420K-73.9%	$856K-12.0%	$3.23M+127%	$4.07M+150%
Derivative Liabilities (Non-Current)	——	——	——	——	——
Accrued expenses and other liabilities	$4.92M—	$4.49M—	$5.37M—	——	——
Total debt	$1.2M—	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	71.4M+57.0%	69.9M+121%	64.5M+146%	59.9M+131%	45.5M+81.3%
Convertible Preferred Stock Authorized Shares	2.6M-73.7%	10M+0.1%	10M-0.1%	10M-0.1%	10M-0.1%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$7K+40.0%	$7K+133%	$6K+100%	$6K+100%	$5K+66.7%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment - Nonvested Awards (Number)	22.9M—	22.9M—	29.4M—	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$1.31-31.4%	$1.31-72.8%	$1.91-100.0%	$1.91-100.0%	$1.91-100.0%
Temporary Equity Attributable to Parent	$24.74M—	$0—	$0—	——	——
Warrants and Rights Outstanding	——	——	——	——	——
Professional service fees	$1.25M-69.3%	$420K-73.9%	$856K-12.0%	$3.23M+127%	$4.07M+150%
R&D services and supplies	$2.86M—	$2.06M—	$2.82M—	$2.1M—	——
Class of Warrant or Right Exercisable	——	——	——	——	——
Class of Warrant or Right, Outstanding	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$125M0.0%	$125M0.0%	$125M0.0%	$125M+66.7%	$125M+66.7%
Common stock, shares issued (in shares)	$71.4M+57.0%	$69.89M+121%	$64.54M+146%	$59.91M+131%	$45.48M+81.3%
Common Stock, Shares, Outstanding	$71.4M+57.0%	$69.89M+121%	$64.54M+146%	$59.91M+131%	$45.48M+81.3%
Derivative Liability, Noncurrent	——	——	——	——	——
Number of milestones accrued	——	——	——	——	——
Number of potential milestones	——	——	——	——	——
Other accrued liabilities	$15K-96.1%	$15K-97.5%	$268K+325%	$265K+176%	$380K+300%
Payments for CVR	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$2.63M-73.7%	$10M+0.1%	$9.99M-0.1%	$9.99M-0.1%	$9.99M-0.1%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	$1.31—	$1.31—	$1.91—	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number	$22.9M—	$22.9M—	$29.43M—	——	——
Weighted average grant price (in dollars per share)	$1.31—	$1.31—	$1.91—	——	——
Exercisable	22.9M—	22.9M—	29.4M—	——	——
Temporary Equity Shares Outstanding	——	——	——	——	——
Warrants And Rights Outstanding	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Opus Genetics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Opus Genetics's total assets?: Opus Genetics (IRD) holds $66.8M in total assets, up 38.7% year over year.
How much debt does Opus Genetics have?: Opus Genetics carries $1.2M in total debt against -$45.8M of shareholders' equity, a debt-to-equity ratio of 0.07.
How much cash does Opus Genetics have?: Opus Genetics holds $60.0M in cash and equivalents.
Can Opus Genetics cover its short-term obligations?: Its current ratio is 7.13 — current assets exceed current liabilities.
Where does Opus Genetics's balance sheet data come from?: Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.